MaxCyte
MXCT
112 hedge funds and large institutions have $98M invested in MaxCyte in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 38 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
0% more funds holding
Funds holding: 112 → 112 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.47% less ownership
Funds ownership: 65.73% → 59.26% (-6.5%)
12% less capital invested
Capital invested by funds: $111M → $98M (-$12.8M)
29% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Asset Management
Paris,
France
|
+$4.43M |
| 2 |
Millennium Management
New York
|
+$1.89M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.64M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.1M |
| 5 |
D.E. Shaw & Co
New York
|
+$585K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$7.26M |
| 2 |
Morgan Stanley
New York
|
-$3.61M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.33M |
| 4 |
BlackRock
New York
|
-$1.18M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$775K |
MXCT Hedge Fund Activity: Q4 2025 in Review
112 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q4 2025, worth a combined $98M — down 12% from $111M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MXCT positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 38 trimmed.
The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $4.43M. The largest seller was Cadian Capital Management, cutting an estimated $7.26M.
- 112 institutional investors held MaxCyte (MXCT) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $98M of MaxCyte stock for Q4 2025, down 12% quarter-over-quarter.
- 20 funds opened new MaxCyte positions in Q4 2025 and 16 closed out, a net change of +4 holders.
- The largest MaxCyte buyer in Q4 2025 was BNP Paribas Asset Management, an estimated $4.43M added.
- The largest MaxCyte seller in Q4 2025 was Cadian Capital Management, an estimated $7.26M sold.
Based on aggregated 13F filings for Q4 2025.